- A metabolic gene signature identified by transcriptional analysis is associated with dedifferentiation of papillary thyroid cancer (PTC).
Why this matters
- This metabolic gene signature may be a useful biomarker of dedifferentiation, which is associated with poor clinical outcomes.
- Expression of the metabolic genes LPCAT2 (OR, 0.424; P=.036), ACOT7 (OR, 11.175; P<.001>, HSD17B8 (OR, 0.049; P<.001>, PDE8B (OR, 0.357; P<.001 and>ST3GAL1 (OR, 0.190; P<.001 were associated with the low-differentiated phenotype in multivariate analysis.>
- The gene signature had an area under the curve of 0.90 for predicting a low-differentiated phenotype.
- The gene signature risk score was associated with T3/T4 stage (OR, 1.651; P=.026), lymph node metastasis (OR, 2.495; P<.001 and>BRAF-V600E mutation (OR, 3.213; P<.001 inversely associated with the>RAS mutation (OR, 0.124; P=.001) in multivariate analysis.
- 502 patients with PTC from The Cancer Genome Atlas cohort.
- Funding: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.
- Retrospective study.